Premium
Magnetic resonance imaging‐guided targeted prostate biopsy: Comparison between computer‐software‐based fusion versus cognitive fusion technique in biopsy‐naïve patients
Author(s) -
Yamada Yasuhiro,
Shiraishi Takumi,
Ueno Akihisa,
Ueda Takashi,
Fujihara Atsuko,
Naitoh Yasuyuki,
Hongo Fumiya,
Ukimura Osamu
Publication year - 2020
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.14127
Subject(s) - medicine , magnetic resonance imaging , prostate cancer , biopsy , radiology , prostate biopsy , image fusion , cancer , prostate , nuclear medicine , fusion , linguistics , philosophy
Objective To compare magnetic resonance imaging‐guided cognitive fusion‐targeted biopsies versus computer‐software‐based fusion‐targeted biopsies in prostate biopsy‐naïve patients. Methods This was a retrospective review of 298 consecutive patients, in which suspected clinically significant prostate cancer lesions were detected on pre‐biopsy magnetic resonance imaging, and cognitive fusion‐targeted biopsies or software‐guided magnetic resonance imaging‐ultrasound fusion‐targeted biopsies was carried out. The positivity rates of any cancer and clinically significant prostate cancer, Gleason score, and maximum cancer core length were compared between the cognitive fusion‐targeted biopsies and software‐guided magnetic resonance imaging‐ultrasound fusion‐targeted biopsies groups. Results The any‐cancer positivity rate was 79.6% (90/113 patients) in the cognitive fusion‐targeted biopsies group and 84.8% (157/185 patients) in the software‐guided magnetic resonance imaging‐ultrasound fusion‐targeted biopsies group ( P = 0.516), and the clinically significant prostate cancer positivity rate was 72.5% (82/113 patients) in the cognitive fusion‐targeted biopsies group and 75.7% (140/185 patients) in the software‐guided magnetic resonance imaging‐ultrasound fusion‐targeted biopsies group ( P = 0.498). Among the patients in which the largest lesion diameter on magnetic resonance imaging was ≤5.0 mm, the clinically significant prostate cancer positivity rate was 39.2% (11/28 patients) in the cognitive fusion‐targeted biopsies group and 66.6% (24/36 patients) in the software‐guided magnetic resonance imaging‐ultrasound fusion‐targeted biopsies group ( P = 0.043). The median maximum cancer core length was 7.5 mm (0.25–16 mm) in the cognitive fusion‐targeted biopsies group and 8 mm (0.2–19 mm) in the software‐guided magnetic resonance imaging‐ultrasound fusion‐targeted biopsies group ( P = 0.040). Conclusions Software‐guided magnetic resonance imaging‐ultrasound fusion‐targeted biopsies offers a greater detection rate for smaller targeted lesions and also superior ability to sample greater cancer core length compared with cognitive fusion‐targeted biopsies. The present results suggest that software‐guided magnetic resonance imaging‐ultrasound fusion‐targeted biopsies might improve biopsy outcomes compared with cognitive fusion‐targeted biopsies.